. Author manuscript; available in PMC: 2023 Jun 1.

Published in final edited form as: Transplant Cell Ther. 2022 Mar 11;28(6):294–302. doi: 10.1016/j.jtct.2022.03.006

Table 1.

Characteristics of the 19 Studies Included in the Systematic Review

CHARACTERISTICS	NO. OF STUDIES (N=19)	REFERENCES
Year Published
2017–2019	6	Gust 2017,⁹ Gofshteyn 2018²⁸, Santomasso 2018¹⁰, Shalabi 2018²⁰, Karschnia 2019⁸, Rubin 2019¹²
2020–2022	17	Belin 2020²¹, Cordeiro 2020¹³, Gajra 2020³³, Maziara 2020³², Ruark 2020¹⁴, Rubin 2020²⁴, Sokolov 2020²⁹, Strati 2020²², Wudhikarn 2020³⁰, Gust 2021²³, Holtzman 2021³¹, Brown 2021³⁴, Maillet 2021²⁵, Yuen 2021³⁵, Greenbaum 2021²⁶, Beuchat 2022³⁶, Wudhikarn 2021²⁷
Sample Size
< 50	7	Shalabi 2018²⁰, Karschnia 2019⁸, Ruark 2020¹⁴, Sokolov 2020²⁹, Holtzman 2021³¹, Brown 2021³⁴, Yuen 2021³⁵
50–99	8	Gofshteyn 2018²⁸, Santomasso 2018¹⁰, Belin 2020²¹, Cordeiro 2020¹³, Wudhikarn 2020³⁰, Maillet 2021²⁵, Beuchat 2022³⁶, Wudhikarn 2021²⁷
100–199	6	Gust 2017,⁹ Rubin 2019¹², Maziara 2020³², Strati 2020²², Gust 2021²³, Greenbaum 2021²⁶
≥200	2	Rubin 2020²⁴, Gajra 2020³³
Age
Pediatric and young adult cohort (mean, SD)^*	4	Gofshteyn 2018 (11.5y, 4.3)²⁸, Shalabi 2018 (17.9y, 6.9)²⁰, Gust 2021 (cEEG-14.3y, 7.5; rEEG- 10.7y, 8.2)²³, Brown 2021³⁴
Adult cohort (mean, SD)^*	15	Gust 2017,⁹ Santomasso 2018¹⁰, Karschnia 2019 (56y, 16.3)⁸, Rubin 2019 (54.6y, 12.3)¹², Belin 2020 (51.7y, 12.8)²¹, Cordeiro 2020 (51.7y, 11.5)¹³, Gajra 2020³³, Maziara 2020³², Ruark 2020 (51.3y, 12.3)¹⁴, Rubin 2020 (60y,12.5)²⁴, Sokolov 2020²⁹, Strati 2020 (54.3y, 14.4)²², Wudhikarn 2020 (55.7y, 15.5)³⁰, Holtzman 2021(53.7y, 12.2)³¹, Maillet 2021(58y,14)²⁵, Yuen 2021³⁵, Greenbaum 2021²⁶, Beuchat 2022 (60y, 11)³⁶, Wudhikarn 2021²⁷
Study Design
prospective cohort	8	Gust 2017,⁹ Santomasso 2018¹⁰,Shalabi 2018²⁰, Belin 2020²¹, Rubin 2020²⁴, Strati 2020²², Gust 2021²³, Maillet 2021²⁵, Greenbaum 2021²⁶, Wudhikarn 2021²⁷
retrospective cohort	9	Gofshteyn 2018²⁸, Karschnia 2019⁸, Cordeiro 2020¹³, Gajra 2020³³, Maziara 2020³², Sokolov 2020²⁹, Wudhikarn 2020³⁰, Holtzman 2021³¹, Brown 2021³⁴, Yuen 2021³⁵, Beuchat 2022³⁶
mixed prospective and retrospective cohort	1	Rubin 2019¹²
cross-sectional	1	Ruark 2020¹⁴
Cancer Type
Diffuse large B-Cell lymphoma (DLBCL)	11	Shalabi 2018²⁰, Belin 2020²¹, Gajra 2020³³, Strati 2020²², Wudhikarn 2020³⁰, Holtzman 2021³¹, Brown 2021³⁴, Maillet 2021²⁵, Yuen 2021³⁵, Greenbaum 2021²⁶, Wudhikarn 2021²⁷
Acute lymphocytic leukemia (ALL)	8	Gofshteyn 2018²⁸, Santomasso 2018¹⁰,Shalabi 2018²⁰, Cordeiro 2020¹³, Ruark 2020¹⁴, Sokolov 2020²⁹, Brown 2021³⁴, Beuchat 2022³⁶
Non-Hodgkins lymphoma (NHL)	4	Cordeiro 2020¹³, Maziara 2020³², Ruark 2020¹⁴, Sokolov 2020²⁹
Chronic lymphocytic leukemia (CLL)	4	Karschnia 2019⁸, Cordeiro 2020¹³, Ruark 2020¹⁴, Sokolov 2020²⁹
Lymphoma (not classified)	4	Gust 2017,⁹ Rubin 2019¹², Rubin 2020²⁴, Beuchat 2022³⁶
Leukemia (not classified)	2	Rubin 2019¹², Rubin 2020²⁴
Follicular Lymphoma	2	Belin 2020²¹, Sokolov 2020²⁹
Hepatocellular Carcinoma	1	Karschnia 2019⁸
Multiple Myeloma	1	Beuchat 2022³⁶
Sarcoma	1	Rubin 2019¹²
CAR-T Cell Target
CD19	17	Gust 2017,⁹ Gofshteyn 2018²⁸, Santomasso 2018¹⁰, Karschnia 2019⁸, Belin 2020²¹, Cordeiro 2020¹³, Gajra 2020³³, Maziara 2020³², Ruark 2020¹⁴, Rubin 2020²⁴, Sokolov 2020²⁹, Strati 2020²², Wudhikarn 2020³⁰, Gust 2021²³, Holtzman 2021³¹, Brown 2021³⁴, Maillet 2021²⁵, Yuen 2021³⁵, Greenbaum 2021²⁶, Beuchat 2022³⁶, Wudhikarn 2021²⁷
CD22	1	Shalabi 2018²⁰
BCMA	1	Yuen 2021³⁵
Not indicated	1	Rubin 2019¹²
CAR-T Product
Axicabtagene ciloleucel	3	Rubin 2020²⁴, Strati 2020²², Holtzman 2021³¹
Tisagenlecleucel	2	Gofshteyn 2018²⁸, Maziara 2020³²
Axicabtagene ciloleucel and Tisagenlecleucel	4	Gajra 2020³³, Belin 2020²¹, Wudhikarn 2020³⁰, Brown 2021³⁴

Mean and SD was calculated using formula by McGrath et al using minimum, maximum and median when mean was not provided.^{8,12–14,21–23,28,30,31} Mean used when provided.^20,24,25